Therapeutic strategies of diabetic nephropathy: Recent progress and future perspectives

Drug Discovery Today

Volumn 20, Issue 3, 2015, Pages 332-346

  Lv, Meng ^a   Chen, Zhuo ^a   Hu, Gaoyun ^a   Li, Qianbin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALISKIREN; ALPHA LIPOID ACID; ALPHA TOCOPHEROL; ALRESTATIN; ANTIDIABETIC AGENT; APOCYNIN; ASCORBIC ACID; CARBOXYLIC ACID DERIVATIVE; DIHYDROLIPOATE; EPALRESTAT; EPLERENONE; FLAVONOID; GKT 136901; HYDANTOIN DERIVATIVE; IRBESARTAN; LINAGLIPTIN; LOSARTAN; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PF 3882845; PONALRESTAT; REACTIVE OXYGEN METABOLITE; SITAGLIPTIN; TETRAMETHYLENEGLUTARIC ACID; TOLRESTAT; UNCLASSIFIED DRUG; VALSARTAN; VAS 2870; VAS 3947; ZOPOLRESTAT; PROTEIN KINASE C BETA;

ANTIINFLAMMATORY ACTIVITY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; KIDNEY FIBROSIS; MINERAL SUPPLEMENTATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NITROSATIVE STRESS; NONHUMAN; OSMOTIC STRESS; OXIDATIVE STRESS; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VITAMIN SUPPLEMENTATION; ANIMAL; DIABETIC NEPHROPATHIES; DRUG DEVELOPMENT; FIBROSIS; METABOLISM; RISK FACTOR;

ANIMALS; DIABETIC NEPHROPATHIES; DRUG DISCOVERY; FIBROSIS; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; PROTEIN KINASE C BETA; RISK FACTORS;

EID: 84925390105     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.10.007     Document Type: Review

References (129)

1. V. Jha Chronic kidney disease: global dimension and perspectives Lancet 382 2013 260 272
2. G. Danaei National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 2011 31 40
3. H.H. Parving Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective Kidney Int. 69 2006 2057 2063
4. R.C. Atkins, and P. Zimmet Diabetic kidney disease: act now or pay later Kidney Int. 77 2010 375 377
5. M.E. Cooper Diabetes: treating diabetic nephropathy - still an unresolved issue Nat. Rev. Endocrinol. 8 2012 515 516
6. T.H. Hostetter Hyperfiltration and glomerulosclerosis Semin. Nephrol. 23 2003 194 199
7. D.K. Singh Oxidative stress in early diabetic nephropathy: fueling the fire Nat. Rev. Endocrinol. 7 2011 176 184
8. J.F. Navarro-Gonzalez Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy Nat. Rev. Nephrol. 7 2011 327 340
9. J.P. Casas Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis Lancet 366 2005 2026 2033
10. D.L. Jennings Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis Diabet. Med. 24 2007 486 493
11. A.L. Mooyaart Genetic associations in diabetic nephropathy Clin. Exp. Nephrol. 54 2013 544 553
12. K. Apel, and H. Hirt Reactive oxygen species: metabolism, oxidative stress, and signal transduction Annu. Rev. Plant Biol. 55 2004 373 399
13. A. Tojo Suppressing renal NADPH oxidase to treat diabetic nephropathy Expert Opin. Ther. Targets 11 2007 1011 1018
14. H. Noh, and G.L. King The role of protein kinase C activation in diabetic nephropathy Kidney Int. 72 2007 S49 S53
15. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
16. T. Nishikawa Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404 2000 787 790
17. J. Wada, and H. Makino Inflammation and the pathogenesis of diabetic nephropathy Clin. Sci. 124 2013 139 152
18. D. Ferenbach Inflammatory cells in renal injury and repair Semin. Nephrol. 27 2007 250 259
19. Y. Liu Cellular and molecular mechanisms of renal fibrosis Nat. Rev. Nephrol. 7 2011 684 696
20. C.E. Hills, and P.E. Squires The role of TGF-β and epithelial-to-mesenchymal transition in diabetic nephropathy Cytokine Growth Factor Rev. 22 2011 131 139
21. G.K. Braga The role of transforming growth factor-beta in diabetic nephropathy Int. J. Med. Genet. 2014 2014 1 6
22. K. Yagi Alternatively spliced variant of Smad2 lacking exon 3: comparison with wild-type Smad2 and Smad3 J. Biol. Chem. 274 1999 703 709
23. M. Petersen Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis Kidney Int. 73 2007 705 715
24. M.A. Pohl Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations J. Am. Soc. Nephrol. 16 2005 3027 3037
25. W.C. Cushman Effects of intensive blood-pressure control in type 2 diabetes mellitus N. Engl. J. Med. 362 2010 1575
26. M.L. Onozato Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB Kidney Int. 61 2002 186 194
27. A.H. Gradman Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients Circulation 111 2005 1012 1018
28. J.A. Staessen Oral renin inhibitors Lancet 368 2006 1449 1456
29. R. Pinto, and A.H. Gradman Direct renin inhibition: an update Curr. Hypertens. Rep. 11 2009 456 462
30. Y.-F. Dong Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice J. Hypertens. 28 2010 1554 1565
31. H.H. Parving Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) J. Renin Angiotensin Aldosterone Syst. 13 2012 387 393
32. J.J. McMurray Aliskiren, ALTITUDE, and the implications for ATMOSPHERE Eur. J. Heart Fail. 14 2012 341 343
33. F. Ismail-Beigi Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Lancet 376 2010 419 430
34. DCCT/EDIC Research Group Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes N. Engl. J. Med. 2011 2011 2366 2376
35. S. Hattori Sitagliptin reduces albuminuria in patients with type 2 diabetes Endocr. J. 58 2010 69 73
36. P.-H. Groop Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction Diabetes Care 36 2013 3460 3468
37. S. Shibata Podocyte as the target for aldosterone roles of oxidative stress and Sgk1 Hypertension 49 2007 355 364
38. S. Nakano Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD (P) H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats Hypertens. Res. 28 2005 925 936
39. M.J. Meyers Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a, 4,5-tetrahydro-2H-benzo[g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy J. Med. Chem. 53 2010 5979 6002
40. D.W. Piotrowski Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy J. Med. Chem. 55 2012 7957 7966
41. M.S. Farvid Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation Diabetes Res. Clin. Pract. 93 2011 86 94
42. M.S. Farvid Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes Diabetes Care 28 2005 2458 2464
43. K. Asaba Double-edged action of SOD mimetic in diabetic nephropathy J. Cardiovasc. Pharmacol. 49 2007 13 19
44. S. Golbidi Antioxidants in the treatment of diabetes Curr. Diabetes Rev. 7 2011 106 125
45. G. Bjelakovic Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis JAMA 297 2007 842 857
46. E.R. Miller 3rd Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality Ann. Intern. Med. 142 2005 37 46
47. G.W. Davison Molecular detection of exercise-induced free radicals following ascorbate prophylaxis in type 1 diabetes mellitus: a randomised controlled trial Diabetologia 51 2008 2049 2059
48. K.V. Ramana Aldose reductase: new insights for an old enzyme Biomol. Concepts 2 2011 103 114
49. S.S.M. Chung Contribution of polyol pathway to diabetes-induced oxidative stress J. Am. Soc. Nephrol. 14 2003 233 236
50. H. Liu Genetic deficiency of aldose reductase counteracts the development of diabetic nephropathy in C57BL/6 mice Diabetologia 54 2011 1242 1251
51. B.L. Mylari A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2 H-pyridazin-3-one and congeners J. Med. Chem. 48 2005 6326 6339
52. S. Hayman, and J.H. Kinoshita Isolation and properties of lens aldose reductase J. Biol. Chem. 240 1965 877 882
53. J.H. Kinoshita Mechanisms initiating cataract formation proctor lecture Invest. Ophthalmol. Vis. Sci. 13 1974 713 724
54. J. Jedziniak, and J. Kinoshita Activators and inhibitors of lens aldose reductase Invest. Ophthalmol. Vis. Sci. 10 1971 357 366
55. D. Dvornik Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor Science 182 1973 1146 1148
56. M.A. Ramirez, and N.L. Borja Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy Pharmacother: J. Hum. Pharmacol. Drug Ther. 28 2008 646 655
57. I. Itagaki The effect of an aldose reductase inhibitor (epalrestat) on diabetic nephropathy in rats Diabetes Res. Clin. Pract. 25 1994 147 154
58. A. Beyer-Mears Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus Pharmacology 52 1996 292 302
59. P. Huang Role of aldose reductase in the high glucose induced expression of fibronectin in human mesangial cells Mol. Biol. Rep. 37 2010 3017 3021
60. S.M. Donnelly Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat Biochem. Cell Biol. 74 1996 355 362
61. D.J. Sellers, and R. Chess-Williams The effect of sorbinil, an aldose reductase inhibitor, on aortic function in control and streptozotocin-induced diabetic rats J. Auton. Pharmacol. 20 2000 15 22
62. M. Kurono Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability Biochem. Pharmacol. 71 2006 338 353
63. V.R. Drel Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells Free Radic. Biol. Med. 40 2006 1454 1465
64. M. Chatzopoulou Novel aldose reductase inhibitors: a patent survey (2006-present) Expert Opin. Ther. Pat. 22 2012 1303 1323
65. H. Kumar Novel insights into the structural requirements for the design of selective and specific aldose reductase inhibitors J. Mol. Model 18 2012 1791 1799
66. K. Block Oxidative stress and redox-signaling in renal cell cancer J.R. Amato, Emerging Research and Treatments in Renal Cell Carcinoma 2012 InTech 137 166
67. G. Cheng Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5 Gene 269 2001 131 140
68. P. Moulton The inhibition of flavoproteins by phenoxaiodonium, a new iodonium analogue Eur. J. Pharmacol. 401 2000 115 120
69. B. O'Donnell Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase Biochem. J. 290 1993 41 49
70. V.F. Ximenes The oxidation of apocynin catalyzed by myeloperoxidase: proposal for NADPH oxidase inhibition Arch. Biochem. Biophys. 457 2007 134 141
71. M.S. Petronio Apocynin: chemical and biophysical properties of a NADPH oxidase inhibitor Molecules 18 2013 2821 2839
72. K. Asaba Effects of NADPH oxidase inhibitor in diabetic nephropathy Kidney Int. 67 2005 1890 1898
73. S.M. Nam Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property Diabetes Res. Clin. Pract. 83 2009 176 182
74. J.M. Simons Metabolic activation of natural phenols into selective oxidative burst agonists by activated human neutrophils Free Radic. Biol. Med. 8 1990 251 258
75. S. Heumuller Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant Hypertension 51 2008 211 217
76. M. Sedeek Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy Am. J. Physiol. Renal. 299 2010 F1348 F1358
77. C. Stielow Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells Biochem. Biophys. Res. Commun. 344 2006 200 205
78. H. ten Freyhaus Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation Cardiovasc. Res. 71 2006 331 341
79. S. Altenhofer The NOX toolbox: validating the role of NADPH oxidases in physiology and disease Cell. Mol. Life Sci. 69 2012 2327 2343
80. M. Sedeek Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes Clin. Sci. (Lond.) 124 2013 191 202
81. D. Tampe, and M. Zeisberg Potential approaches to reverse or repair renal fibrosis Nat. Rev. Nephrol. 10 2014 226 237
82. T. Inoguchi Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes JAMA 298 2007 1396 1400
83. M. Fujii Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD (P) H oxidase Kidney Int. 78 2010 905 919
84. J. Zheng Phycocyanin and phycocyanobilin from Spirulina platensis protect against diabetic nephropathy by inhibiting oxidative stress Am. J. Physiol. Regul. Integr. Comp. Physiol. 304 2013 R110 R120
85. J. Streeter Opportunity Nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease Cardiovasc. Ther. 31 2013 125 137
86. M.L. Onozato Dual blockade of aldosterone and angiotensin II additively suppresses TGF-β and NADPH oxidase in the hypertensive kidney Nephrol. Dial. Transpl. 22 2007 1314 1322
87. N. Sawada Novel aspects of the roles of Rac1 GTPase in the cardiovascular system Curr. Opin. Pharmacol. 10 2010 116 121
88. C. Baigent The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
89. S.C. Palmer Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis Ann. Intern. Med. 157 2012 263 275
90. T. Almquist Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease Eur. J. Clin. Invest. 44 2014 276 284
91. M. Meier Deletion of protein kinase C-epsilon signaling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo J. Am. Soc. Nephrol. 18 2007 1190 1198
92. J. Menne Inhibition of protein kinase C in diabetic nephropathy - where do we stand? Nephrol. Dial. Transplant. 24 2009 2021 2023
93. J. Menne Dual inhibition of classical protein kinase C-alpha and protein kinase C-beta isoforms protects against experimental murine diabetic nephropathy Diabetes 62 2013 1167 1174
94. K.R. Tuttle The effect of ruboxistaurin on nephropathy in type 2 diabetes Diabetes Care 28 2005 2686 2690
95. A.B. Sanz NF-kappaB in renal inflammation J. Am. Soc. Nephrol. 21 2010 1254 1262
96. A.T. Dinkova-Kostova Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress Proc. Natl. Acad. Sci. U. S. A. 102 2005 4584 4589
97. M.B. Sporn New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress J. Nat. Prod. 74 2011 537 545
98. P.E. Pergola Bardoxolone methyl and kidney function in CKD with type 2 diabetes N. Engl. J. Med. 365 2011 327 336
99. M. Okamoto A novel CC chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models Biol. Pharm. Bull. 35 2011 2069 2074
100. T.J. Sullivan Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications J. Pharmacol. Exp. Ther. 342 2012 234
101. M. Bonanomi Male fertility: core chemical structure in pharmacological research Contraception 65 2002 317 320
102. A. Ble Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis Am. J. Nephrol. 34 2011 367 372
103. E. Mora Bindarit: an anti-inflammatory small molecule that modulates the NFkappaB pathway Cell Cycle 11 2012 159 169
104. P.A. Voziyan, and B.G. Hudson Pyridoxamine: the many virtues of a maillard reaction inhibitor Ann. N. Y. Acad. Sci. 1043 2005 807 816
105. E.J. Lewis Pyridorin in type 2 diabetic nephropathy J. Am. Soc. Nephrol. 23 2012 131 136
106. L. Kennedy Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes Am. J. Nephrol. 31 2010 110 116
107. A. Owada Effect of long-term administration of prostaglandin I2 in incipient diabetic nephropathy Nephron 92 2002 788 796
108. M. Watanabe Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I(2) analog, beraprost sodium Am. J. Nephrol. 30 2009 1 11
109. M. Petersen Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis Kidney Int. 73 2008 705 715
110. J.A. Moon IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy Kidney Int. 70 2006 1234 1243
111. S.G. Adler Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria Clin. J. Am. Soc. Nephrol. 5 2010 1420 1428
112. T. Ak, and I. Gülçin Antioxidant and radical scavenging properties of curcumin Chem. Biol. Interact. 174 2008 27 37
113. A. Rajeswari Curcumin protects mouse brain from oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine Eur. Rev. Med. Pharmacol. Sci. 10 2006 157
114. S. Sharma Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats Clin. Exp. Pharmacol. Physiol. 33 2006 940 945
115. J. Huang Curcumin ameliorates diabetic nephropathy by inhibiting the activation of the SphK1-S1P signaling pathway Mol. Cell. Endocrinol. 365 2013 231 240
116. P. Khajehdehi Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study Scand. J. Urol. Nephrol. 45 2011 365 370
117. S.C. Gupta Therapeutic roles of curcumin: lessons learned from clinical trials AAPS J. 15 2013 195 218
118. H. Taniguchi Pirfenidone in idiopathic pulmonary fibrosis Eur. Respir. J. 35 2009 821 829
119. H.P. Misra, and C. Rabideau Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals Mol. Cell. Biochem. 204 2000 119 126
120. J.F. Chen Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized rats Am. J. Physiol. Renal. Physiol. 304 2013 F676 F685
121. S.P. RamachandraRao Pirfenidone is renoprotective in diabetic kidney disease J. Am. Soc. Nephrol. 20 2009 1765 1775
122. K. Sharma Pirfenidone for diabetic nephropathy J. Am. Soc. Nephrol. 22 2011 1144 1151
123. Z.Z. Peng Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells Nephrology (Carlton) 14 2009 565 572
124. L.H. Wang Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice Pharmacology 88 2011 88 99
125. B.X. Li Fluorofenidone attenuates renal interstitial fibrosis in the rat model of obstructive nephropathy Mol. Cell. Biochem. 354 2011 263 273
126. Q. Yuan Fluorofenidone attenuates tubulointerstitial fibrosis by inhibiting TGF-β1-induced fibroblast activation Am. J. Nephrol. 34 2011 181 194
127. J. Chen Synthesis and structure-activity relationship of 5-substituent-2(1H)-pyridone derivatives as anti-fibrosis agents Bioorg. Med. Chem. Lett. 22 2012 2300 2302
128. L. Wu Design, synthesis and anti-fibrosis activity study of N(1)-substituted phenylhydroquinolinone derivatives Molecules 17 2012 1373 1387
129. E.J. Horwitz, and J.R. Schelling Treatment of albuminuria due to diabetic nephropathy: recent trial results J. Clin. Invest. 4 2014 327 341